What was the market valuation of the UK pharmacovigilance market in 2024?

The market valuation was 392.66 $ Million in 2024. Read More

What is the projected market valuation for the UK pharmacovigilance market by 2035?

The projected valuation for 2035 is 1025.05 $ Million. Read More

What is the expected CAGR for the UK pharmacovigilance market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period is 9.12 %. Read More

Which service type had the highest valuation in the UK pharmacovigilance market in 2024?

Pharmacovigilance Consulting had the highest valuation at 192.9 $ Million in 2024. Read More

What are the two main deployment modes in the UK pharmacovigilance market?

The two main deployment modes are Cloud-Based, valued at 200.0 $ Million, and On-Premise, valued at 192.66 $ Million in 2024. Read More

Which end user segment is projected to have the highest growth in the UK pharmacovigilance market?

Pharmaceutical Companies, with a valuation of 200.0 $ Million in 2024, are projected to have the highest growth. Read More

What is the valuation range for Adverse Event Reporting in the UK pharmacovigilance market?

The valuation range for Adverse Event Reporting is from 78.53 $ Million to 204.12 $ Million. Read More

Which key player is recognized as a leader in the UK pharmacovigilance market?

IQVIA is recognized as a leading player in the UK pharmacovigilance market. Read More

What is the valuation for Scheduled Reporting in the UK pharmacovigilance market?

Scheduled Reporting had a valuation of 155.34 $ Million in 2024. Read More

How does the valuation of Risk Assessment compare to that of Data Mining in the UK pharmacovigilance market?

Risk Assessment was valued at 62.03 $ Million, while Data Mining was valued at 59.2 $ Million in 2024. Read More

UK Pharmacovigilance Market

ID: MRFR/MED/49690-HCR

200 Pages

Nidhi Mandole

Last Updated: February 06, 2026

UK Pharmacovigilance Market Research Report: Size, Share, Trend Analysis By Service Type (Adverse Event Reporting, Risk Assessment, Data Mining, Pharmacovigilance Consulting), By Deployment Mode (Cloud-Based, On-Premise), By Source (Spontaneous Reporting, Literature Reports, Scheduled Reporting), and By End-user (Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations) - Growth Outlook & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1.1 EXECUTIVE SUMMARY
1.1.1 Market Overview
1.1.2 Key Findings
1.1.3 Market Segmentation
1.1.4 Competitive Landscape
1.1.5 Challenges and Opportunities
1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
2.1 MARKET INTRODUCTION
2.1.1 Definition
2.1.2 Scope of the study
2.1.2.1 Research Objective
2.1.2.2 Assumption
2.1.2.3 Limitations
2.2 RESEARCH METHODOLOGY
2.2.1 Overview
2.2.2 Data Mining
2.2.3 Secondary Research
2.2.4 Primary Research
2.2.4.1 Primary Interviews and Information Gathering Process
2.2.4.2 Breakdown of Primary Respondents
2.2.5 Forecasting Model
2.2.6 Market Size Estimation
2.2.6.1 Bottom-Up Approach
2.2.6.2 Top-Down Approach
2.2.7 Data Triangulation
2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
3.1 MARKET DYNAMICS
3.1.1 Overview
3.1.2 Drivers
3.1.3 Restraints
3.1.4 Opportunities
3.2 MARKET FACTOR ANALYSIS
3.2.1 Value chain Analysis
3.2.2 Porter's Five Forces Analysis
3.2.2.1 Bargaining Power of Suppliers
3.2.2.2 Bargaining Power of Buyers
3.2.2.3 Threat of New Entrants
3.2.2.4 Threat of Substitutes
3.2.2.5 Intensity of Rivalry
3.2.3 COVID-19 Impact Analysis
3.2.3.1 Market Impact Analysis
3.2.3.2 Regional Impact
3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
4.1 Chemicals and Materials, BY Service Type (USD Million)
4.1.1 Adverse Event Reporting
4.1.2 Risk Assessment
4.1.3 Data Mining
4.1.4 Pharmacovigilance Consulting
4.2 Chemicals and Materials, BY Deployment Mode (USD Million)
4.2.1 Cloud-Based
4.2.2 On-Premise
4.3 Chemicals and Materials, BY Source (USD Million)
4.3.1 Spontaneous Reporting
4.3.2 Literature Reports
4.3.3 Scheduled Reporting
4.4 Chemicals and Materials, BY End User (USD Million)
4.4.1 Pharmaceutical Companies
4.4.2 Biotechnology Companies
4.4.3 Contract Research Organizations
5 SECTION V: COMPETITIVE ANALYSIS
5.1 Competitive Landscape
5.1.1 Overview
5.1.2 Competitive Analysis
5.1.3 Market share Analysis
5.1.4 Major Growth Strategy in the Chemicals and Materials
5.1.5 Competitive Benchmarking
5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
5.1.7 Key developments and growth strategies
5.1.7.1 New Product Launch/Service Deployment
5.1.7.2 Merger & Acquisitions
5.1.7.3 Joint Ventures
5.1.8 Major Players Financial Matrix
5.1.8.1 Sales and Operating Income
5.1.8.2 Major Players R&D Expenditure. 2023
5.2 Company Profiles
5.2.1 IQVIA (US)
5.2.1.1 Financial Overview
5.2.1.2 Products Offered
5.2.1.3 Key Developments
5.2.1.4 SWOT Analysis
5.2.1.5 Key Strategies
5.2.2 PPD (US)
5.2.2.1 Financial Overview
5.2.2.2 Products Offered
5.2.2.3 Key Developments
5.2.2.4 SWOT Analysis
5.2.2.5 Key Strategies
5.2.3 Syneos Health (US)
5.2.3.1 Financial Overview
5.2.3.2 Products Offered
5.2.3.3 Key Developments
5.2.3.4 SWOT Analysis
5.2.3.5 Key Strategies
5.2.4 Wuxi AppTec (CN)
5.2.4.1 Financial Overview
5.2.4.2 Products Offered
5.2.4.3 Key Developments
5.2.4.4 SWOT Analysis
5.2.4.5 Key Strategies
5.2.5 Celerion (US)
5.2.5.1 Financial Overview
5.2.5.2 Products Offered
5.2.5.3 Key Developments
5.2.5.4 SWOT Analysis
5.2.5.5 Key Strategies
5.2.6 Medpace (US)
5.2.6.1 Financial Overview
5.2.6.2 Products Offered
5.2.6.3 Key Developments
5.2.6.4 SWOT Analysis
5.2.6.5 Key Strategies
5.2.7 Pharmerit International (US)
5.2.7.1 Financial Overview
5.2.7.2 Products Offered
5.2.7.3 Key Developments
5.2.7.4 SWOT Analysis
5.2.7.5 Key Strategies
5.2.8 Veristat (US)
5.2.8.1 Financial Overview
5.2.8.2 Products Offered
5.2.8.3 Key Developments
5.2.8.4 SWOT Analysis
5.2.8.5 Key Strategies
5.3 Appendix
5.3.1 References
5.3.2 Related Reports
6 LIST OF FIGURES
6.1 MARKET SYNOPSIS
6.2 UK MARKET ANALYSIS BY SERVICE TYPE
6.3 UK MARKET ANALYSIS BY DEPLOYMENT MODE
6.4 UK MARKET ANALYSIS BY SOURCE
6.5 UK MARKET ANALYSIS BY END USER
6.6 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
6.7 RESEARCH PROCESS OF MRFR
6.8 DRO ANALYSIS OF CHEMICALS AND MATERIALS
6.9 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
6.10 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
6.11 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
6.12 CHEMICALS AND MATERIALS, BY SERVICE TYPE, 2024 (% SHARE)
6.13 CHEMICALS AND MATERIALS, BY SERVICE TYPE, 2024 TO 2035 (USD Million)
6.14 CHEMICALS AND MATERIALS, BY DEPLOYMENT MODE, 2024 (% SHARE)
6.15 CHEMICALS AND MATERIALS, BY DEPLOYMENT MODE, 2024 TO 2035 (USD Million)
6.16 CHEMICALS AND MATERIALS, BY SOURCE, 2024 (% SHARE)
6.17 CHEMICALS AND MATERIALS, BY SOURCE, 2024 TO 2035 (USD Million)
6.18 CHEMICALS AND MATERIALS, BY END USER, 2024 (% SHARE)
6.19 CHEMICALS AND MATERIALS, BY END USER, 2024 TO 2035 (USD Million)
6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
7.1 LIST OF ASSUMPTIONS
7.1.1
7.2 UK MARKET SIZE ESTIMATES; FORECAST
7.2.1 BY SERVICE TYPE, 2025-2035 (USD Million)
7.2.2 BY DEPLOYMENT MODE, 2025-2035 (USD Million)
7.2.3 BY SOURCE, 2025-2035 (USD Million)
7.2.4 BY END USER, 2025-2035 (USD Million)
7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

UK Chemicals and Materials Market Segmentation

Chemicals and Materials By Service Type (USD Million, 2025-2035)

Adverse Event Reporting
Risk Assessment
Data Mining
Pharmacovigilance Consulting

Chemicals and Materials By Deployment Mode (USD Million, 2025-2035)

Cloud-Based
On-Premise

Chemicals and Materials By Source (USD Million, 2025-2035)

Spontaneous Reporting
Literature Reports
Scheduled Reporting

Chemicals and Materials By End User (USD Million, 2025-2035)

Pharmaceutical Companies
Biotechnology Companies
Contract Research Organizations

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓